FDA Found Repeat Quality Deficiencies at Valsartan Manufacturer’s Facility

Drug Industry Daily
A A
In another twist in the worldwide recall of the contaminated blood pressure medication, valsartan, the FDA released two Form 483 reports issued to the API’s manufacturer in China after inspections in 2016 and 2017.

To View This Article:

Login

Subscribe To Drug Industry Daily